A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

The Pew Charitable Trusts held a one-day conference, “A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations” on Thursday, January 31, 2013.

As multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options. Leaders representing the drug industry, health care providers, government regulators and payors came together to advance this concept and explore its feasibility from a business and public health perspective.

The Pew Charitable Trusts makes every effort to comply with federal, state and local government ethics rules when hosting events. Please make sure that your participation is consistent with applicable ethics rules.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up